COVID-19: Our Current Path Forward

W. L. GORE & ASSOCIATES ANNOUNCES ENCOURAGING SIX-MONTH RESULTS WITH ITS NOVEL BIOSYNTHETIC TISSUE VALVE

At the American Heart Association Virtual Scientific Sessions 2020.

GORE REDUCE CLINICAL STUDY FIVE-YEAR RESULTS DEMONSTRATE THAT PFO CLOSURE WITH THE GORE® CARDIOFORM SEPTAL OCCLUDER PROVIDES SAFE LONG-TERM REDUCTION OF RECURRENT STROKE

FIVE-YEAR RESULTS OF THE GORE® EXCLUDER® ILIAC BRANCH ENDOPROSTHESIS PIVOTAL U.S. MULTICENTER STUDY CONFIRM SAFETY, EFFICACY AND DURABILITY

Gore Unveils Next Evolution for TIPS Procedures: Lasting Diameter Control

GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion builds on a legacy of proven patency

Gore Receives Health Canada Approval for GORE® VIABAHN® Endoprosthesis Innovations, Treating Peripheral Vascular Disease

Longer and Lower Profile Options Now Available in Canada to Treat More Patient Anatomies

Final Subject Enrolled in Early Feasibility Study of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis

Antegrade iteration accepted into study – advancing this branched, all-in-one system

One-Year Results in Japanese Clinical Study Affirms the GORE® VIABAHN® Endoprosthesis as a Device-of-Choice for Treating Complex SFA Disease

New clinical study shows excellent patency consistent with previous study results of self-expanding stent-graft in long, complex SFA lesions

Gore REVISE Clinical Study Demonstrates Superiority of GORE VIABAHN Endoprosthesis

GORE Device Outperforms Standard Treatment Option for Stenoses or Thrombotic Occlusions

First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study

Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population